NOTCH1 and B-cell chronic lymphocytic leukemia: Suppressing the activity of Notch1 or Notch2 resulted in an enhanced response of CLL cells to fludarabine (Del Papa et al., 2019) or venetoclax (Fiorcari et al., 2022), respectively, indicating that natural compounds with the ability to decrease Notch activation may be able to overcome resistance in CLL.